Serum and Tissue c-erb B2, bcl-2, and Mutant p53 Oncoprotein Levels in Nasopharyngeal Cancer

REFERENCES

• Feinmesser R., Miyazaki I., Cheung R., Freeman J. L., Noyek A. M., Dosch H. M. Diagnosis of Nasopharyngeal Carcinoma by DNA Amplification of Tissue Obtained by Fine-Needle Aspiration. N. Engl. J. Med. 1992; 326: 17–21
   PubMed Web of Science ®Google Scholar
• Altun M., Fandi A., Dupuis O., Cvitkovic E., Krajina Z., Eschwege F. Undifferentiated Nasopharyngeal Cancer. Current Diagnostic and Therapeutic Aspects. Int. J. Radiation Oncol. Biol. Phys. 1995; 32: 859–877
   PubMed Web of Science ®Google Scholar
• Meden H., Marx D., Fattahi A., Rath W., Kron M., Wuttke W., Schauer A., Kuhn W. Elevated Serum Levels of a c-erb B2 Oncogene Product in Ovarian Cancer Patients and in Pregnancy. J. Cancer Res. Clin. Oncol. 1994; 120: 378–381
   PubMed Web of Science ®Google Scholar
• Beckhardt R. N., Kiyokawa N., Xi L., Liu T. J., Hung M. C., el-Naggar A. K., Zhang H. Z., Clayman G. L. HER-2/neu Oncogene Characterization in Head and Neck Squamous Cell Carcinoma. Arch. Otolaryngol. Head Neck Surg. 1995; 121: 1265–1270
   PubMed Web of Science ®Google Scholar
• Ravdin P. M. Prognostic Factors in Breast Cancer. ASCO Educational Book, M. C. Perry. WB Saunders, Philadelphia 1997; 217–227
   Google Scholar
• Seshadri R., Firgaira F. A., Horsfall D. J., McCaul K., Setlur V., Kitchen P. Clinical Significance of her-2/neu Amplification in Primary Breast Cancer. J. Clin. Oncol. 1993; 11: 1936–1942
   PubMed Web of Science ®Google Scholar
• Bianchi S., Paglierani M., Zampi G., Cardona G., Cataliotti L., Bonardi R., Ciatto S. Prognostic Significance of c-erb B2 Expression in Node Negative Breast Cancer. Br. J. Cancer 1993; 67: 625–629
   PubMed Web of Science ®Google Scholar
• Yazici H., Muslumanoglu M., Guzey D., Yasasever V., Ozbek U., Dalay N. Amplification in Tumors and Benign Tissue of Breast Cancer Patients. Cancer Lett. 1996; 107: 235–239
   PubMed Web of Science ®Google Scholar
• Fehm T., Maimonis P., Katalinic A., Jager W. H. The Prognostic Significance of c-erb B2 Serum Protein in Metastatic Breast Cancer. Oncology 1998; 55: 33–38
   PubMed Web of Science ®Google Scholar
• Harpole D. H., Herndon J. E., Wolfe W. G., Iglehart J. D., Marks J. R. A Prognostic Model of Recurrence and Death in Stage I Non-small Cell Lung Cancer Utilizing Presentation Histopathology and Oncoprotein Expression. Cancer Res. 1995; 55: 51–56
   PubMed Web of Science ®Google Scholar
• Lee E. Y., Cibull M. L., Strodel W. E., Haley J. V. Expression of HER-2/neu Oncoprotein and Epidermal Growth Factor Receptor and Prognosis in Gastric Carcinoma. Arch. Pathol. Lab. Med. 1994; 118: 235–239
   PubMed Web of Science ®Google Scholar
• Oka K., Nakano T., Arai T. c-erb B2 Oncoprotein Expression Is Associated with Poor Prognosis in Squamous Cell Carcinoma of the Cervix. Cancer 1994; 73: 668–671
   Web of Science ®Google Scholar
• Meden H., Kuhn W. Overexpression of the c-erb B2 (HER-2/neu) in Ovarian Cancer. A New Prognostic Factor. Eur. J. Obstet. Gynecol. Reprod. Biol. 1997; 71: 173–179
   PubMed Web of Science ®Google Scholar
• Yazici H., Altun M., Alatli C., Dogan O., Dalay N. c-erb B2 Gene Amplification in Nasopharyngeal Cancer. Cancer Invest. 2000; 18: 6–10
   PubMed Web of Science ®Google Scholar
• Kuerbitz S. J., Plunkett B. S., Walsh W. V., Kastan M. B. Wild Type p53 Is a Cell Cycle Checkpoint Determinant Following Irradiation. Proc. Natl. Acad. Sci. U.S.A. 1992; 89: 7491–7495
   PubMed Web of Science ®Google Scholar
• Silvestrini R., Benini E., Daidone M. G., Veneroni S., Boracchi P., Cappelletti V., Di Fronzo G., Veronesi U. P53 as an Independent Prognostic Marker in Lymph-Node Negative Breast Cancer Patients. J. Natl. Cancer. Inst. 1993; 85: 965–970
   PubMed Web of Science ®Google Scholar
• Starzynska T., Bromley M., Ghosh A., Stern P. L. Prognostic Significance of p53 Overexpression in Gastric and Colorectal Carcinoma. Br. J. Cancer 1992; 66: 558–562
   PubMed Web of Science ®Google Scholar
• Hockenberry D. M., Nunez G., Milliman C., Schreiber R. D., Korsmeyer S. J. bcl-2 Is an Inner Mitochondrial Membrane Protein That Blocks Programmed Cell Death. Nature 1990; 348: 334–336
   PubMed Web of Science ®Google Scholar
• Hague A., Moorghen M., Hicks D., Chapman M., Paraskeva C. bcl-2 Expression in Human Colorectal Adenomas and Carcinomas. Oncogene 1994; 9: 3367–3370
   PubMed Web of Science ®Google Scholar
• Lu Q. L., Elia G., Lucas S., Thomas J. A. bcl-2 Protooncogene Expression in Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma. Int. J. Cancer 1993; 53: 29–35
   PubMed Web of Science ®Google Scholar
• Yasasever V., Karaloglu D., Yazici H., Olgac V., Dalay N. Cancer Associated Marker Proteins in the Tumor and Benign Tissue of Breast Cancer Patients. J. Tumor Marker Oncol. 1993; 8: 33–38
   Google Scholar
• Karaloglu D., Yasasever V., Kizir A., Dalay N. Serum Levels of Mutant p53 Protein in Cancer. J. Exp. Clin. Cancer Res. 1996; 15: 335–339
   Web of Science ®Google Scholar
• Lowry O. H., Rosebrough N. J., Farr A. L., Randall R. J. Protein Measurement with the Folin Phenol Reagent. J. Biol. Chem. 1951; 193: 265–275
   PubMed Web of Science ®Google Scholar
• Rodrigo J. P., Ramos S., Lazo P. S., Alvarez I., Suarez C. Amplification of erb B2 Oncogenes in Squamous Cell Carcinomas of the Head and Neck. Eur. J. Cancer 1996; 32: 2004–2010
   Google Scholar
• Leonard J. H., Kearsley J. H., Chenevix-Trench G., Hayward N. K. Analysis of Gene Amplification in Head and Neck Squamous Cell Carcinoma. Int. J. Cancer 1991; 48: 511–515
   PubMed Web of Science ®Google Scholar
• Craven J. M., Pavelic Z. P., Stambrook P. J., Pavelic L., Gapany M., Kelley D. J., Gapany S., Gluckman J. L. Expression of c-erb B2 Gene in Human Head and Neck Carcinoma. Anticancer Res. 1992; 12: 2273–2276
   PubMed Web of Science ®Google Scholar
• Beckhardt R. N., Kiyokawa N., Xi L., Liu T. J., Hung M. C., el-Naggar A. K., Zhang H. Z., Clayman G. L. HER-2 neu Oncogene Characterization in Head and Neck Squamous Cell Carcinoma. Arch. Otolaryngol. Head Neck Surg. 1995; 121: 1265–1270
   PubMed Web of Science ®Google Scholar
• Yasasever V., Karaloglu D., Yazici H., Onat H., Dalay N. Serum neu Oncoprotein Levels as a Tumor Marker in Breast Cancer. J. Tumor Marker Oncol. 1992; 7: 33–42
   Google Scholar
• Yazici H., Dolapcioglu K., Buyru F., Dalay N. Utility of c-erb B2 Expression in Tissue and Sera of Ovarian Cancer Patients. Cancer Invest. 2000; 18(2)112–116
   Google Scholar
• Mutirangura A., Tanunyutthawongese C., Pornthanakasem W., Kerekhanjanarong V., Sriuranpong V., Yenrudi S., Supiyaphun P., Voravud N. Genomic Alterations in Nasopharyngeal Carcinoma: Loss of Heterozygosity and Epstein-Barr Virus Infection. Br. J. Cancer 1997; 76: 770–776
   PubMed Web of Science ®Google Scholar
• Chakrani F., Armand J. P., Lenoir G., Ju L. Y., Liang J. P., May E., May P. Mutations Clustered in Exon 5 of the p53 Gene in Primary Nasopharyngeal Carcinomas from Southeast Asia. Int. J. Cancer 1995; 61: 316–320
   PubMed Web of Science ®Google Scholar
• Gulley M. L., Burton M. P., Allred D. C., Nicholls J. M., Amin M. B., Ro J. Y., Schneider B. G. Epstein-Barr Virus Infection Is Associated with p53 Accumulation in Nasopharyngeal Carcinoma. Hum. Pathol. 1998; 29: 252–259
   PubMed Web of Science ®Google Scholar
• Nasrin N., Taiba K., Hannan N., Hannan M., al-Sedairy S. A Molecular Study of EBV DNA and p53 Mutations in Nasopharyngeal Carcinoma of Saudi Arab Patients. Cancer Lett. 1994; 82: 189–198
   PubMed Web of Science ®Google Scholar
• Sheu L. F., Chen A., Tseng H. H., Leu F. J., Lin J. K., Ho K. C., Meng C. L. Assessment of p53 Expression in Nasopharyngeal Carcinoma. Hum. Pathol. 1995; 26: 380–386
   PubMed Web of Science ®Google Scholar
• Levesque M. A., D'Costa M., Diamandis E. P. p53 Protein Is Absent from the Serum of Patients with Lung Cancer. Br. J. Cancer 1996; 74: 1434–1440
   PubMed Web of Science ®Google Scholar
• Angelopoulou K., Diamandis E. P. Detection of the TP53 Tumor Supressor Gene Product and p53 Auto-Antibodies in the Ascites of Women with Ovarian Cancer. Eur. J. Cancer 1997; 33: 115–121
   PubMed Web of Science ®Google Scholar
• Mudenda B., Green J. A., Green B., Jenkins J. R., Robertson L., Tarunina M., Leinster S. J. The Relationship Between Serum p53 Autoantibodies and Characteristics of Human Breast Cancer. Br. J. Cancer 1994; 69: 1115–1119
   PubMed Web of Science ®Google Scholar
• Green J. A., Mudenda B., Jenkins J., Leinster S. J., Tarunina M., Green B., Robertson L. Serum p53 Autoantibodies: Incidence in Familial Breast Cancer. Eur. J. Cancer 1994; 30A: 580–584
   PubMed Web of Science ®Google Scholar
• Meden H., Marx D., Rath W., Kron M., Fattahi-Meibodi A., Hinney B., Kuhn W., Schauer A. Overexpression of the Oncogene c-erb B2 in Primary Ovarian Cancer: Evaluation of the Prognostic Value in a Cox Proportional Hazards Multiple Regression. Int. J. Gynecol. Pathol. 1994; 13: 45–53
   PubMed Web of Science ®Google Scholar
• Lomo J., Blomhoff H. K., Beiske K., Stokke T., Smeland E. B. TGFβ1 and cAMP Promote Apoptosis in Resting Human B Lymphocytes. J. Immunol. 1995; 154: 1634–1643
   PubMed Web of Science ®Google Scholar
• Choi M. S.K., Boise L. H., Gottschalk A. R., Quintans J., Thompson C. B., Klaus G. G. The Role of bcl-xL in CD40-Mediated Rescue from Anti-μ-induced Apoptosis in WEHI-231 B Lymphoma Cells. Eur. J. Immunol. 1995; 25: 1352–1357
   PubMed Web of Science ®Google Scholar
• Gottschalk A. R., Boise L. H., Thompson C. B., Quintans J. Identification of Immunosuppressant-Induced Apoptosis in a Murine B-cell Line and Its Prevention by bcl-x but Not bcl-2. Proc. Natl. Acad. Sci. U.S.A. 1994; 91: 7350–7354
   PubMed Web of Science ®Google Scholar
• Holder M. J., Wang H., Milner A. E., Casamayor M., Armitage R., Spriggs M. K., Fanslow W. C., MacLennan I. C., Gregory C. D., Gordon J. Suppression of Apoptosis in Normal and Neoplastic Human B Lymphocytes by CD40 Ligand Is Independent of bcl-2 Induction. Eur. J. Immunol. 1993; 23: 2368–2371
   PubMed Web of Science ®Google Scholar
• Merritt A. J., Patten C. S., Watson A. J.M., Loh D. Y., Nakayama K., Nakayama K., Hickman J. A. Differential Expression of bcl-2 in Intestinal Epithelia. Correlation with Attenuation of Apoptosis in Colonic Crypts and the Incidence of Colonic Neoplasia. J. Cell. Sci. 1995; 108: 2261–2271
   PubMed Web of Science ®Google Scholar
• Henderson S., Rowe M., Gregory C., Croom-Carter D., Wang F., Longnecker R., Kieff E., Rickinson A. Induction of bcl-2 Expression by Epstein-Barr Virus Latent Membrane Protein 1 Protects Infected Cells from Programmed Cell Death. Cell 1991; 65: 1107–1115
   PubMed Web of Science ®Google Scholar
• Tsujimoto Y. Overexpression of the Human bcl-2 Gene Product Results in Growth Enhancement of Epstein-Barr Virus-Immortalized B Cells. Proc. Nat. Acad. Sci. U.S.A. 1989; 86: 1958–1962
   PubMed Web of Science ®Google Scholar
• Watson A. J.M., Merritt A. J., Jones L. S., Askew J. N., Anderson E., Becciolini A., Balzi M., Potten C. S., Hickman J. A. Evidence for Reciprocity of bcl-2 and p53 Expression in Human Colorectal Adenomas and Carcinomas. Br. J. Cancer 1996; 73: 889–895
   PubMed Web of Science ®Google Scholar
• Sheu L. F., Chen. A., Meng C. L., Ho K. C., Lin F. G., Lee W. H. Analysis of bcl-2 Expression in Normal, Inflamed, Dysplastic Nasopharyngeal Epithelia and Nasopharyngeal Carcinoma: Association with p53 Expression. Hum. Pathol. 1997; 28: 556–562
   PubMed Web of Science ®Google Scholar